This study is the first placebo-controlled clinical trial to investigate a treatment for MRONJ in patients for whom the condition is established.
Although all recommendations were endorsed, an expert panel also added discussion points regarding treatments for reducing skeletal-related events in and improving survival in patients with bone metastases.
A case series study demonstrated the importance of timely, preventive dental assessment for patients with multiple myeloma.
A comparison study presented at the 2017 SABCS sought to determine the effectiveness of bisphosphonates with denosumab for skeletal-related events in women with breast cancer metastases to bone.
The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast, and colon cancers, according to two recent studies.
Nitrogen-containing bisphosphonates have been associated with reduced risk of endometrial cancer, according to research.
In elderly patients with moderate- to high-risk early stage breast cancer for whom standard chemotherapy is too toxic, capecitabine did not improve outcomes when tested as monotherapy, according to recent data.
Data from two randomized controlled trials suggest that bisphosphonate use does not protect against postmenopausal breast cancer, according to research.
Treatment with zoledronate, a bisphosphonate, did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase 3 clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
Adding bisphosphonates to myeloma treatment decreases fractures of the vertebra and bone pain, affirm the results of a review of 20 trials.
